COMPARE · Data as of August 21, 2026
ADMA vs HRMY
Verdict: Side-by-side breakdown using the Bull Rankings model. ADMA scored 81.3, HRMY scored 88.7 — HRMY leads.
Compare another set
ADMA
ADMA Biologics, Inc.
81.3
$9.84 · $2.2B
fundamentals as of
Score gap
7.4
HRMY leads
HRMY
Harmony Biosciences Holdings, Inc.
88.7
$38.07 · $2.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestHRMY12.3x
- Fastest growthHRMY+24.3%
- Strongest balance sheetHRMY0.16
- Highest qualityADMA84 / 100
- Largest discount to fair valueHRMY-75%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ADMA
stronger →← stronger
HRMY
84
Qualityreturns · margins · balance sheet
80
77
Growthrevenue & earnings expansion
91
83
Valuevaluation vs sector peers
95
HRMY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ADMA
HRMY
$116mC
FCF
$355mC
+8.0%B
Rev
+24.3%A-
1.11C
D/E
0.16B+
14.1xA-
P/E
12.3xA
0.60A-
PEG
0.44A
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ADMA
HRMY
32% below
Price vs fair valuelower is cheaper
75% below
~4%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-18%/yr
+14%
1-yr DCF upside
+207%
+47%
5-yr DCF upside
+304%
+117%
10-yr DCF upside
+507%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ADMA
Why this score
- Buying back stock
- Durable high returns
- Earnings outpace cash
HRMY
Why this score
- Durable high returns
The companies
ADMAADMA Biologics, Inc.
Why now
Biotechnology · market cap $2.2b. Down 52% from 52-week high of $20.46 — deep drawdown territory. PEG 0.60 — paying under fair value for the growth rate. 5 sell-side analysts rate this a Buy with a mean 1-yr target of $17.00 (implying +73% upside).
Moat
Net margin 33% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HRMYHarmony Biosciences Holdings, Inc.
Why now
Biotechnology · market cap $2.2b. 7% off the 52-week high of $40.87. Revenue growing +24%, comfortably above the S&P median. PEG 0.44 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $46.10 (implying +21% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
The model favors HRMY (88.2) over ADMA (81.7) primarily due to its superior Growth pillar (91 vs. 77), reflected in HRMY's +24.3% revenue growth (A-). However, a contrarian might prefer ADMA given its significantly lower implied growth of 3% per year, suggesting less optimism is priced into its future performance compared to HRMY's -18%.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ADMA and HRMY diverge
On the headline score the gap is 7.4 points in favor of HRMY. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- GrowthADMA 76.9 · HRMY 91.5HRMY +14.6
- ValueADMA 83.0 · HRMY 95.4HRMY +12.4
- QualityADMA 84.1 · HRMY 79.9ADMA +4.2
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.